Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8449MR)

This product GTTS-WQ8449MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8449MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13395MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ3055MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ11089MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ1220MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ15780MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ3612MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ5691MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ12522MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW